Shareholder analysis


Shares issued

As at 31st August 2023, the number of ordinary shares in issue was 74,142,147.

Major shareholders

As at 31st August 2023, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company.

No of ordinary shares %
Balderton Capital III, LP 6,813,196 9.19
Blind Trust (Richard Sharp) 4,891,444 6.60
Mr Timothy Brian Bunting 4,856,717 6.55
Credit Suisse 4,579,509 6.18
Genostics Company Ltd 3,295,659 4.45
HSBC Holdings Plc 3,236,737 4.37
Hargreaves Lansdown Asset Management 3,137,967 4.23
Chelverton Asset Management 3,007,500 4.06

Director shareholdings

No of shares No of share options No of warrants
Tim Bunting 4,856,717
Alistair Macdonald 55,555 619,641
John Goold 1,150,000


Shares not in public hands

In accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 31st August 2023, 20.78% of the Company’s AIM securities was not in public hands.

Restrictions on transfer of Aim Securities

There are no restrictions on the transfer of securities.

UK City Code on takeovers and mergers

Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.

Details of other exchanges or trading platforms

Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.

Page last updated: 20th November 2023